Conestoga Capital Advisors LLC Increases Stake in Stevanato Group S.p.A. (NYSE:STVN)

Conestoga Capital Advisors LLC raised its position in Stevanato Group S.p.A. (NYSE:STVN) by 5.3% in the fourth quarter, Holdings Channel reports. The fund owned 8,082,996 shares of the company’s stock after buying an additional 407,086 shares during the period. Stevanato Group makes up approximately 2.3% of Conestoga Capital Advisors LLC’s portfolio, making the stock its 16th biggest holding. Conestoga Capital Advisors LLC’s holdings in Stevanato Group were worth $176,128,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Squarepoint Ops LLC increased its position in Stevanato Group by 65.6% during the second quarter. Squarepoint Ops LLC now owns 17,302 shares of the company’s stock worth $317,000 after buying an additional 6,853 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Stevanato Group by 222.3% during the second quarter. The Manufacturers Life Insurance Company now owns 251,606 shares of the company’s stock worth $4,614,000 after acquiring an additional 173,546 shares during the period. Truist Financial Corp increased its holdings in shares of Stevanato Group by 47.0% in the 2nd quarter. Truist Financial Corp now owns 26,034 shares of the company’s stock valued at $477,000 after purchasing an additional 8,321 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Stevanato Group during the 3rd quarter valued at approximately $263,000. Finally, nVerses Capital LLC acquired a new position in Stevanato Group during the third quarter worth $84,000.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Morgan Stanley reiterated an “equal weight” rating and issued a $23.00 price target (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Bank of America upped their price objective on Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Finally, Wolfe Research assumed coverage on Stevanato Group in a research report on Friday, December 13th. They set an “outperform” rating and a $28.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Stevanato Group currently has a consensus rating of “Moderate Buy” and a consensus price target of €28.60 ($29.18).

Stevanato Group Stock Performance

NYSE:STVN opened at €22.59 ($23.05) on Monday. Stevanato Group S.p.A. has a 1-year low of €16.56 ($16.90) and a 1-year high of €34.73 ($35.44). The firm has a 50-day moving average of €21.73 and a two-hundred day moving average of €20.50. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. The stock has a market cap of $6.84 billion, a P/E ratio of 48.06, a PEG ratio of 7.76 and a beta of 0.56.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings data on Tuesday, November 5th. The company reported €0.12 ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of €0.13 ($0.13) by (€0.01) (($0.01)). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The firm had revenue of €277.90 million for the quarter, compared to analyst estimates of €274.36 million. During the same quarter in the previous year, the company earned $0.16 EPS. The company’s quarterly revenue was up 2.4% compared to the same quarter last year. On average, research analysts expect that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.